Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 2 · 50%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 50%

Vomiting · non‐immune adults and children travelling to or living in malaria‐endemic settings

Mefloquine showed no clear difference in vomiting compared with atovaquone‐proguanil; GRADE not reported.

1 finding from 1 review

Mefloquine for preventing malaria during travel to endemic areas 2017 · Cochrane Headline outcomes only
RR 1.31 [0.49, 3.5]
1 study · 976 participants
GRADE not reported

Vomiting · Non‐immune adults and children travelling to malaria‐endemic settings

Mefloquine led to lower vomiting compared with doxycycline; GRADE not reported.

1 finding from 1 review

Mefloquine for preventing malaria during travel to endemic areas 2017 · Cochrane Headline outcomes only
RR 0.18 [0.12, 0.27]
4 studies · 5071 participants
GRADE not reported

Vomiting · HIV‐uninfected pregnant women

Mefloquine leads to higher AEs: vomiting compared with sulfadoxine‐pyrimethamine (high certainty).

1 finding from 1 review

Mefloquine for preventing malaria in pregnant women 2018 · Cochrane Headline outcomes only
RR 4.76 [4.13, 5.49]
2 studies · 6272 participants
High

Vomiting · HIV‐infected pregnant women

Mefloquine plus cotrimoxazole leads to higher AEs: vomiting compared with cotrimoxazole (high certainty).

1 finding from 1 review

Mefloquine for preventing malaria in pregnant women 2018 · Cochrane Headline outcomes only
RR 7.95 [4.79, 13.18]
1 study · 1055 participants
High